[AMRS] Amyris, Inc.


Type of security: Stock

Sector: Basic Industries

Industry: Major Chemicals

Market Capitalization: 84.47 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 0.71 Change: 0.03 (4.28%)
Ext. hours: 0.7 Change: -0.01 (-1.22%)

chart AMRS

Refresh chart

Strongest Trends Summary For AMRS

AMRS is in the medium-term down -36% in 7 months.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Amyris, Inc., a renewable products company, provides various alternatives to a range of petroleum-sourced products for the specialty chemical and transportation fuel markets worldwide. It builds and applies its industrial synthetic biology platform to design microbes, primarily yeast, to convert plant-sourced sugars into renewable hydrocarbons. The company produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products. It also provides Biofene for specialty chemical applications and transportation fuels, such as diesel. In addition, the company is involved in the development, production, and commercialization of renewable base oils, as well as additives and lubricants for the automotive, industrial, and commercial lubricants markets; and offers natural oils and aroma chemicals for the flavors and fragrances market. It has a strategic partnership with Total for the production and commercialization of diesel and jet fuels. The company was former

Fundamental Ratios
Shares Outstanding211.17 M EPS-6.31 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -15.42% Sales Growth - Q/Q-32.05% P/E-0.48
P/E To EPS Growth P/S1.87 P/BV-0.46 Price/Cash Per Share1.86
Price/Free Cash Flow-0.94 ROA-34.92% ROE36.34% ROI-54.44%
Current Ratio1.34 Quick Ratio1.12 Long Term Debt/Equity17.06 Debt Ratio-0.28
Gross Margin21.8% Operating Margin-217.94% Net Profit Margin-149.48% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities7.32 M Cash From Investing Activities-1.07 M Cash From Operating Activities-3.28 M Gross Profit1.23 M
Net Profit-52.24 M Operating Profit-25.16 M Total Assets193.05 M Total Current Assets69.3 M
Total Current Liabilities51.65 M Total Debt242.99 M Total Liabilities378.61 M Total Revenue7.87 M
Technical Data
High 52 week9.2 Low 52 week2.8 Last close4.9 Last change-0.61%
RSI67.19 Average true range0.68 Beta1.24 Volume768.67 K
Simple moving average 20 days11.04% Simple moving average 50 days23.44% Simple moving average 200 days-17.11%
Performance Data
Performance Week-1.21% Performance Month47.15% Performance Quart37.83% Performance Half-34.49%
Performance Year-16.67% Performance Year-to-date46.71% Volatility daily13.26% Volatility weekly29.65%
Volatility monthly60.76% Volatility yearly210.47% Relative Volume154.97% Average Volume2.63 M
New High New Low


2019-03-24 14:30:00 | Bragar Eagel & Squire, P.C. is Investigating Amyris, Inc. AMRS on Behalf of Stockholders and Encourages AMRS Investors to Contact the Firm

2019-03-23 12:36:00 | 3 Takeaways From Amyris' Q4 2018 Earnings Report

2019-03-22 16:40:04 | Glancy Prongay & Murray LLP Announces Investigation on Behalf of Amyris, Inc. Investors AMRS

2019-03-21 19:50:00 | Glancy Prongay & Murray LLP Announces Investigation on Behalf of Amyris, Inc. Investors AMRS

2019-03-20 21:36:00 | INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Amyris, Inc. Investors AMRS

2019-03-20 13:47:00 | Here's Why Amyris Collapsed Today

2019-03-19 13:05:19 | Amyris Signs $300M Deal For Fermentation-Derived CBD Products

2019-03-19 05:37:23 | Edited Transcript of AMRS earnings conference call or presentation 18-Mar-19 8:30pm GMT

2019-03-18 20:39:35 | Amyris Inc AMRS Q4 2018 Earnings Conference Call Transcript

2019-03-18 16:28:44 | Amyris Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Announces Signing of $300 Million Definitive Cannabinoid Agreement

2019-03-18 16:19:21 | Amyris Finalizes Cannabinoid Development, Licensing and Commercialization Agreement Containing $300 Million of R&D and Milestone Payments and a Long-Term Royalty Stream

2019-03-12 08:30:00 | Amyris to Present at 31st Annual Roth Conference on Tuesday, March 19, 2019

2019-03-11 10:30:02 | Analysts Estimate Amyris AMRS to Report a Decline in Earnings: What to Look Out for

2019-03-11 09:52:51 | Did You Manage To Avoid Amyris’s NASDAQ:AMRS Devastating 93% Share Price Drop?

2019-03-10 14:00:00 | A Massive Disruption Could Be on the Way for Marijuana: 3 Stocks Poised to Profit

2019-03-05 08:30:00 | Amyris to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on Monday, March 18, 2019

2019-03-01 15:00:00 | Will Cannabis Producers Ditch Greenhouses for Bioreactors?

2019-02-13 07:30:00 | Signals Point To A Resurgence In Gold That Could Rival The Cannabis Renaissance

2019-02-12 08:30:00 | Amyris Is Selected by NIH Grant Recipient, IDRI, to Engineer Molecules for Vaccine Adjuvant Applications

2019-02-11 08:30:00 | Amyris Appoints Industry Veteran as President, Sweeteners and Ingredients, to Deliver Accelerated Growth

2019-02-08 13:35:00 | These 4 Marijuana Stocks Could Be Positioned For A Big Month

2019-02-06 13:52:42 | Amyris Stock Can Run Much Higher Than You Think

2019-02-05 16:53:09 | What Is Amyris AMRS, And Why Is Its Stock Soaring?

2019-02-05 13:50:00 | These Marijuana Stocks Should Be On Your Radar

2019-02-05 13:24:49 | Pot Without Plants Is Goal of New Cannabis Fermentation Venture

2019-02-05 12:49:09 | Option Bulls Flock to Penny Stock After Weed Deal

2019-02-05 12:46:17 | Amyris News: AMRS Stock Explodes on Cannabinoid Deal

2019-02-05 12:12:00 | Here's Why Amyris Is Soaring Today

2019-02-05 08:00:00 | Amyris Announces $255 Million Cannabinoid Development, Licensing and Commercialization Agreement ? Represents Largest Collaboration Agreement to Date for Amyris

2019-02-01 11:30:00 | LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index

2019-01-19 17:58:00 | Amyris Has Big Growth Plans Again. It Will Likely Fail to Meet Them Again

2018-12-31 08:30:00 | Amyris Announces Signing of Nutritional Product Royalty Agreement

2018-12-23 03:44:26 | Hedge Funds Are Crazy About Amyris Inc AMRS

2018-12-20 08:58:13 | Phil Hempleman’s Ardsley Partners’ Returns, AUM and Holdings

2018-12-12 08:30:00 | Amyris Receives GRAS Notification from FDA for its New, Sugarcane-Derived, Zero Calorie Sweetener

2018-12-11 17:13:33 | Amyris Closes on Debt Solution

2018-12-10 16:13:36 | Health Care Digest: Where were the women in Gilead's CEO search — and more

2018-12-10 08:30:00 | Amyris and ADL Bionatur Solutions Expand Production Agreement to Meet Growing Demand

2018-12-07 08:36:55 | Amyris Takes Major Step Forward in Addressing its Convertible Debt

2018-12-04 08:30:00 | Amyris Celebrates Launch of New Zero Calorie, Naturally-Derived Sweetener

2018-12-03 12:25:19 | Company behind Chanel perfume gets into sweetener business

2018-12-03 09:43:47 | Once a cleantech darling, this East Bay company looks to pour it on with syn-bio sweetener

2018-12-03 08:46:22 | U.S. and China set to finalize a trade deal in the next three months

2018-12-03 07:00:00 | Amyris Partners with Camil Alimentos to Deliver Zero Calorie Sweetener Made from Sugarcane to Brazilian Consumers

2018-11-30 08:57:32 | Amyris Partners with Givaudan to Introduce a Tabletop Application for its Zero Calorie, Naturally Sourced Sweetener

2018-11-16 12:25:00 | Here's Why Amyris Can't Stop Sliding This Week

2018-11-14 11:17:00 | Here's Why Amyris Is Getting Obliterated Today

2018-11-14 03:54:39 | Edited Transcript of AMRS earnings conference call or presentation 13-Nov-18 9:30pm GMT

2018-11-13 16:01:40 | Amyris Reports Third Quarter 2018 Financial Results

2018-11-13 08:17:11 | Amyris Q3 Earnings Outlook